Acclinate key facts
as of Oct 2026- Developer of a digital health platform designed to facilitate an increase in representation and diversity of their genomic research and clinical trials.
- Acclinate is valued at approximately $40.0M as of Oct 2026 (last reported valuation).
- It has raised $15.6M across 3 recorded rounds; the latest was Seed Round ($3.5M) in Feb 2026.
- Notable investors include Techstars, Google for Startups, Gaingels, gener8tor, Realm Capital Ventures — 24 tracked in total.
- Acclinate has filed 3 Form Ds with the SEC since 2022, most recently Apr 2026 ($3.5M sold to 5 investors).
- Status: Privately Held (backing).
Acclinate's last reported valuation, May 2024. Nothing priced has surfaced since.
- ·The complete investor list: 24 names
- ·Watch Acclinate: the Monday email on marks, rounds and moves
Acclinate funding rounds
3 roundsWho backs Acclinate
24+Membership and data by Private Market View
Acclinate valuation
Acclinate's last reported valuation was $40 million in May 2024. No priced round, secondary trade or fund mark has surfaced since.
How much has Acclinate raised?
Acclinate has raised $15.6 million across 3 recorded rounds since 2022. The largest was a $6 million early-stage round in May 2024; the most recent was a $3.5 million seed round in Feb 2026.
Acclinate has filed 3 Form Ds with the SEC since 2022, most recently in Apr 2026 ($3.5 million sold to 5 investors).
Acclinate investors
24 investors are on record for Acclinate, including Techstars, Google for Startups, Gaingels and gener8tor. By type, the record holds 4 venture capital firms and 1 family office. The seed round in Feb 2026 drew 5 investors.
About Acclinate
Developer of a digital health platform designed to facilitate an increase in representation and diversity of their genomic research and clinical trials. The company's platform utilizes machine learning and predictive analytics to automate the identification, education, engagement, and retention of willing and diverse genomic research and clinical trial participants, enabling biopharmaceutical research organizations to decrease the overall cost of drug development.
- Sector
- Healthcare
- HQ
- Birmingham, AL, United States
- Founded
- 2020
- Employees
- 62
- Website
- acclinate.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.